IQWiG Backs Novartis’ Jetrea, Drops Almirall’s Constella On Same Day
Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.
Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.